Form 4: Revance Therapeutics Director Chris Nolet Disposes of Shares Following Merger Agreement

Director Chris Nolet reports the disposal of Revance Therapeutics shares and restricted stock awards following the completion of a merger with Crown Laboratories.

Summary

• Chris Nolet, a director of Revance Therapeutics, filed a Form 4 detailing changes in beneficial ownership.
• On February 4, 2025, Nolet disposed of 28,606 shares of common stock at a price of $3.65 per share.
• These shares were tendered for purchase pursuant to a cash tender offer related to the merger agreement with Crown Laboratories.
• On February 6, 2025, Nolet also disposed of 15,000 shares of common stock.
• Additionally, restricted stock awards held by Nolet were canceled and converted into the right to receive $3.65 per share, as per the merger agreement.

Sentiment

Score: 5

Explanation: The document is a standard SEC filing reporting transactions related to a merger. It is neutral in tone and simply reports facts.

Future Outlook

The document primarily reports on past transactions related to the merger completion and does not contain forward-looking statements about the company's future.

Industry Context

This announcement reflects the completion of a merger, a common occurrence in the biotechnology industry as companies seek to consolidate resources, expand product portfolios, or gain access to new technologies. Mergers often result in changes in ownership and management structures.

Stakeholder Impact

• Shareholders who tendered their shares received $3.65 per share.
• Non-employee members of the Issuer board with restricted stock awards received $3.65 per share for their canceled awards.

Key Dates

Keywords

Revance Therapeutics, Chris Nolet, Form 4, Merger, Crown Laboratories, Share Disposal, Restricted Stock, Beneficial Ownership